More than 500 students with CF have received an estimated $2.4 million in educational funding throughout the 21-year legacy of the scholarship program. It was not necessary for scholarship applicants to have taken, currently take, or intend to take in the future, any medicine or product marketed by AbbVie and this was not a consideration in the selection criteria.
"The AbbVie CF Scholarship provided me with needed financial support to help achieve my educational goals and follow my passion for biology," said 2012 Thriving Graduate Student, Wesley McSparin. "It's really great to see that the program continues to offer a new class of scholars the opportunity to pursue their educational aspirations, and I look forward to voting for a Thriving Undergraduate and Graduate Student."
About Cystic Fibrosis
In patients with CF, a thick, sticky mucus is produced in certain organs throughout the body, most commonly the lungs and digestive system. The mucus build-up in the lungs can cause difficulty breathing and may lead to life-threatening lung infections. In the digestive system, the thick mucus may prevent proper food digestion. More than 70 percent of people with CF are diagnosed by age two.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follo
Copyright©2012 PR Newswire.
All rights reserved